Cargando…

Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT

PURPOSE: The purpose of this study is to investigate whether there are predictors and cutoff points that can predict the acceptable lung dose using intensity-modulated radiation therapy (IMRT) and volume-modulated arc therapy (VMAT) in radiotherapy for upper ang middle esophageal cancer. MATERIAL AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Yan, Chen, Hua, Wang, Hao, Duan, Yanhua, Feng, Aihui, Huang, Ying, Gu, Hengle, Kong, Qing, Xu, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529030/
https://www.ncbi.nlm.nih.gov/pubmed/34692508
http://dx.doi.org/10.3389/fonc.2021.735062
_version_ 1784586378499063808
author Shao, Yan
Chen, Hua
Wang, Hao
Duan, Yanhua
Feng, Aihui
Huang, Ying
Gu, Hengle
Kong, Qing
Xu, Zhiyong
author_facet Shao, Yan
Chen, Hua
Wang, Hao
Duan, Yanhua
Feng, Aihui
Huang, Ying
Gu, Hengle
Kong, Qing
Xu, Zhiyong
author_sort Shao, Yan
collection PubMed
description PURPOSE: The purpose of this study is to investigate whether there are predictors and cutoff points that can predict the acceptable lung dose using intensity-modulated radiation therapy (IMRT) and volume-modulated arc therapy (VMAT) in radiotherapy for upper ang middle esophageal cancer. MATERIAL AND METHODS: Eighty-two patients with T-shaped upper-middle esophageal cancer (UMEC) were enrolled in this retrospective study. Jaw-tracking IMRT plan (JT-IMRT), full-arc VMAT plan (F-VMAT), and pactial-arc VMAT plan (P-VMAT) were generated for each patient. Dosimetric parameters such as MLD and V20 of total lung were compared among the three plannings. Ten factors such as PCTV(inferior) length and PCTV(inferior) length/total lung length were calculated to find the predictors and cutoff points of the predictors. All patients were divided into two groups according to the cutoff points, and the dosimetric differences between the two groups of the three plans were compared. ANOVA, receiver operating characteristic (ROC) analysis, and Mann–Whitney U-test were performed for comparisons between datasets. A p <0.05 was considered statistically significant. RESULT: The quality of the targets of the three plannings was comparable. The total lung dose in P-VMAT was significantly lower than that in JT IMRT and F-VMAT. Monitor unit (MU) of F-VMAT and P-VMAT was significantly lower than that of JT IMRT. ROC analysis showed that among JT IMRT, F-VMAT, and P-VMAT, PCTV(i-L), and PCTV(i-L)/TL(L) had diagnostic power to predict the suitability of RT plans according to lung dose constraints of our department. For JT IMRT, the cutoff points of PCTV(i-L) and PCTV(i-L)/TL(L) were 16.6 and 0.59. For F-VMAT, the cutoff points of PCTV(i-L) and PCTV(i-L)/TL(L) were 16.75 and 0.62. For P-VMAT, the cutoff points of PCTV(i-L) and PCTV(i-L)/TL(L) were 15.15 and 0.59. After Mann–Whitney U-test analysis, it was found that among the three plannings, the group with lower PCTV(i-L) and PCTV(i-L)/TL(L) could significantly reduce the dose of total lung and heart (p <0.05). CONCLUSION: PCTV(i-L <)16.6 and PCTV(i-L)/TL(L) <0.59 for JT IMRT, PCTV(i-L <)16.75 and PCTV(i-L)/TL(L) <0.62 for F-VMAT and PCTV(i-L <)15.15, and PCTV(i-L)/TL(L) <0.59 for P-VMAT can predict whether patients with T-shaped UMEC can meet the lung dose limits of our department.
format Online
Article
Text
id pubmed-8529030
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85290302021-10-22 Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT Shao, Yan Chen, Hua Wang, Hao Duan, Yanhua Feng, Aihui Huang, Ying Gu, Hengle Kong, Qing Xu, Zhiyong Front Oncol Oncology PURPOSE: The purpose of this study is to investigate whether there are predictors and cutoff points that can predict the acceptable lung dose using intensity-modulated radiation therapy (IMRT) and volume-modulated arc therapy (VMAT) in radiotherapy for upper ang middle esophageal cancer. MATERIAL AND METHODS: Eighty-two patients with T-shaped upper-middle esophageal cancer (UMEC) were enrolled in this retrospective study. Jaw-tracking IMRT plan (JT-IMRT), full-arc VMAT plan (F-VMAT), and pactial-arc VMAT plan (P-VMAT) were generated for each patient. Dosimetric parameters such as MLD and V20 of total lung were compared among the three plannings. Ten factors such as PCTV(inferior) length and PCTV(inferior) length/total lung length were calculated to find the predictors and cutoff points of the predictors. All patients were divided into two groups according to the cutoff points, and the dosimetric differences between the two groups of the three plans were compared. ANOVA, receiver operating characteristic (ROC) analysis, and Mann–Whitney U-test were performed for comparisons between datasets. A p <0.05 was considered statistically significant. RESULT: The quality of the targets of the three plannings was comparable. The total lung dose in P-VMAT was significantly lower than that in JT IMRT and F-VMAT. Monitor unit (MU) of F-VMAT and P-VMAT was significantly lower than that of JT IMRT. ROC analysis showed that among JT IMRT, F-VMAT, and P-VMAT, PCTV(i-L), and PCTV(i-L)/TL(L) had diagnostic power to predict the suitability of RT plans according to lung dose constraints of our department. For JT IMRT, the cutoff points of PCTV(i-L) and PCTV(i-L)/TL(L) were 16.6 and 0.59. For F-VMAT, the cutoff points of PCTV(i-L) and PCTV(i-L)/TL(L) were 16.75 and 0.62. For P-VMAT, the cutoff points of PCTV(i-L) and PCTV(i-L)/TL(L) were 15.15 and 0.59. After Mann–Whitney U-test analysis, it was found that among the three plannings, the group with lower PCTV(i-L) and PCTV(i-L)/TL(L) could significantly reduce the dose of total lung and heart (p <0.05). CONCLUSION: PCTV(i-L <)16.6 and PCTV(i-L)/TL(L) <0.59 for JT IMRT, PCTV(i-L <)16.75 and PCTV(i-L)/TL(L) <0.62 for F-VMAT and PCTV(i-L <)15.15, and PCTV(i-L)/TL(L) <0.59 for P-VMAT can predict whether patients with T-shaped UMEC can meet the lung dose limits of our department. Frontiers Media S.A. 2021-10-07 /pmc/articles/PMC8529030/ /pubmed/34692508 http://dx.doi.org/10.3389/fonc.2021.735062 Text en Copyright © 2021 Shao, Chen, Wang, Duan, Feng, Huang, Gu, Kong and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shao, Yan
Chen, Hua
Wang, Hao
Duan, Yanhua
Feng, Aihui
Huang, Ying
Gu, Hengle
Kong, Qing
Xu, Zhiyong
Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT
title Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT
title_full Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT
title_fullStr Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT
title_full_unstemmed Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT
title_short Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT
title_sort investigation of predictors to achieve acceptable lung dose in t-shaped upper and middle esophageal cancer with imrt and vmat
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529030/
https://www.ncbi.nlm.nih.gov/pubmed/34692508
http://dx.doi.org/10.3389/fonc.2021.735062
work_keys_str_mv AT shaoyan investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT chenhua investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT wanghao investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT duanyanhua investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT fengaihui investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT huangying investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT guhengle investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT kongqing investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat
AT xuzhiyong investigationofpredictorstoachieveacceptablelungdoseintshapedupperandmiddleesophagealcancerwithimrtandvmat